AMA CPT® Assistant - 2006 Issue 11 (November)
Pathology and Laboratory: Drug Testing (November 2006)
November 2006 page 22b Pathology and Laboratory: Drug Testing, 80101 (Q&A) Question If a patient is tested for opiates and barbiturates, how many times is code 80101 , Drug screen, qualitative; single drug class method (eg, immunoassay, enzyme assay), each drug class , reported? For code 80101 , each single drug class method tested and reported is to be counted as one drug class. If a sample is analyzed by five separate class-specific immunoassays and reported separately, code 80101 should be reported five times. Similarly, if a sample is run on a rapid assay kit composed of five classspecific immunoassays in...
Subscribe or sign in to view the full article.
Article Overview
This article addresses a pathology and laboratory drug testing coding question from CPT® Assistant. It is focused on how a laboratory should report drug class screening when multiple classes are tested and reported separately, and it is intended for coders, laboratory billing staff, and compliance professionals working with CPT guidance.
Why This Topic Matters
Drug testing reporting can affect claim accuracy, unit reporting, and documentation consistency. Readers need the article to understand the CPT Assistant guidance discussed for laboratory drug screen reporting in a multi-class testing scenario.
Article Sections
-
Question
Presents the coding question posed by the article about reporting a laboratory drug testing service when more than one drug class is involved.
-
Answer
Explains the CPT Assistant guidance discussed in the article and how the service is reported when multiple drug classes are tested and separately reported.
-
Example
Provides a brief laboratory scenario illustrating the general testing situation addressed in the Q&A.
What You Will Learn
- The topic area covered by the CPT Assistant drug testing Q&A
- How the article frames reporting considerations for multi-class laboratory drug screening
- The type of laboratory scenario used to illustrate the guidance
- The audience and compliance relevance of the discussion
Who Should Read This
- Medical coders
- Laboratory billing staff
- Compliance professionals
- Pathology and laboratory billing teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com
